Patents by Inventor Rodney Caughren Schnur

Rodney Caughren Schnur has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Ansamycin derivatives as antioncogene and anticancer agents
    Patent number: 5932566
    Abstract: A compound of the formula ##STR1## and pharmaceutically acceptable salts and prodrugs thereof wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are as defined below, methods and intermediates useful in the preparation thereof, pharmaceutical compositions thereof and methods of treatment therewith. The compounds of the above formula are useful in inhibiting oncogene products and as antitumor and anticancer agents.
    Type: Grant
    Filed: March 25, 1996
    Date of Patent: August 3, 1999
    Assignee: Pfizer Inc.
    Inventors: Rodney Caughren Schnur, Mikel Paul Moyer, Randall James Gallaschun
  • Alkynyl and azido-substituted 4-anilinoquinazolines
    Patent number: 5747498
    Abstract: The invention relates to compounds of the formula ##STR1## and to pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, n and m are as defined herein. The compounds of formula I are useful in the treatment of hyperproliferative diseases, such as cancer. The invention further relates to processes of making the compounds of formula I and to methods of using such compounds in the treatment of hyperproliferative diseases.
    Type: Grant
    Filed: May 28, 1996
    Date of Patent: May 5, 1998
    Assignee: Pfizer Inc.
    Inventors: Rodney Caughren Schnur, Lee Daniel Arnold
  • Alkynl and azido-substituted 4-anilinoquinazolines
    Patent number: RE41065
    Abstract: The invention relates to compounds of the formula and to pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, n and m are as defined herein. The compounds of formula I are useful in the treatment of hyperproliferative diseases, such as cancer. The invention further relates to processes of making the compounds of formula I and to methods of using such compounds in the treatment of hyperproliferative diseases.
    Type: Grant
    Filed: February 27, 2008
    Date of Patent: December 29, 2009
    Assignees: Pfizer, Inc., OSI Pharmaceuticals, Inc.
    Inventors: Rodney Caughren Schnur, Lee Daniel Arnold